Compare TRMB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMB | BIIB |
|---|---|---|
| Founded | 1978 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 24.2B |
| IPO Year | 1990 | 1991 |
| Metric | TRMB | BIIB |
|---|---|---|
| Price | $83.32 | $181.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 23 |
| Target Price | $93.88 | ★ $176.48 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.47 | ★ 10.97 |
| Revenue | $3,600,900,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | $56.99 | ★ $16.52 |
| Revenue Growth | N/A | ★ 4.77 |
| 52 Week Low | $52.91 | $110.04 |
| 52 Week High | $87.50 | $185.17 |
| Indicator | TRMB | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 72.92 |
| Support Level | $79.97 | $174.53 |
| Resistance Level | $82.07 | $182.94 |
| Average True Range (ATR) | 1.85 | 5.22 |
| MACD | 0.61 | 0.25 |
| Stochastic Oscillator | 91.08 | 83.54 |
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).